Muhammad Umer Asghar is an expert in Infectiology at University of Ottawa (Canada). Muhammad Umer Asghar has authored 12 publications, the most recent in 2025. SLR score: 537 (community average: 125). How the SLR is computed.

LeadR Profile

Muhammad Umer Asghar University of Ottawa Canada
537 ScienceLeadR Reputation 537
Network Map

Infectiology

Subspecialties: Immunology - Biochemistry - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

I hold a Ph.D. in Biotechnology from the National Probiotic Lab at the National Institute for Biotechnology and Genetic Engineering (NIBGE), Pakistan, with collaborative research training at the Emerging Pathogens Institute, University of Florida, USA. My academic and research background spans a multidisciplinary interface of biotechnology, microbiology, structural biology, molecular biology, microbial genomics, and bioinformatics. My research is primarily focused on the hospital microbiome, particularly its role in the emergence and persistence of hospital-acquired infections (HAIs) and antimicrobial resistance (AMR). I am committed to addressing the urgent need for effective infection control strategies in healthcare settings, especially within lower-middle-income countries such as Pakistan. By investigating local microbial reservoirs and resistance patterns, my work aims to develop sustainable, microbiome-informed solutions to combat AMR and HAIs. A key aspect of my research involves the identification of novel antimicrobial compounds from microbial communities and the formulation of potent, bio-based biocidal disinfectants to enhance hospital hygiene practices. These efforts are grounded in translational science with a strong emphasis on eco-friendly, scalable interventions suitable for resource-limited healthcare systems. I am currently exploring early-stage research opportunities in both academia and industry and remain open to interdisciplinary collaborations that align with my broader goal of advancing sustainable approaches to infectious disease prevention, microbial risk mitigation, and global health security.

Organizations

Career arc: 2021 - 2026

Source: PubMed

University of Ottawa

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 12

Citations

Citations: 8 1st author: 8 Last author: 1 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Journey of B Cell Dysregulation in Rheumatoid Arthritis: Insights from Immunogenomics.
PMID 41239950 — cells, arthritis, arthritis, rheumatoid, b-lymphocytes
Immunol Invest20250
Unveiling the spectrum of vancomycin resistance in Staphylococcus aureus from Hospital-acquired urinary tract infections (HA-UTI) in cardiac patients.
PMID 41065916 — genes, staphylococcus, urinary tract, vancomycin resistance, vancomycin, urinary tract infections, staphylococcus aureus, virulence, infections
Mol Biol Rep20250
A metagenomics-based approach to understanding the transmission of healthcare-associated antimicrobial resistance in Pakistan.
PMID 40749656 — genes, genes, rrna, genome, metagenomics, intensive care units, environment, microbiota, hazardous substances
J Hazard Mater20250
Antimicrobial Peptides as Next-Generation Disinfectants: Tackling Biocide and Antimicrobial Resistance in Hospital Hygiene - A Narrative Review.
PMID 40833722 — hygiene, biofilms, solutions, probiotics, infections, disinfectants
Probiotics Antimicrob Proteins20250
Next generation antimicrobial peptide disinfectant targeting biocide and vancomycin resistant staphylococcus aureus through integrated in Silico and in vitro validation.
PMID 40751059 — genes, staphylococcus, vancomycin-resistant staphylococcus aureus, stress, physiological, oxidative stress, bacitracin, vancomycin, staphylococcus aureus, disinfectants
Sci Rep20250

LeadR Networks

Main global connection map